DaraVRD/DaraVCD

Phase 2Small molecule

UUniversity of Alabama at Birmingham

DaraVRD/DaraVCD is one of 6 small molecule programs targeting Minimal Residual Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Minimal Residual DiseaseRecruiting

Minimal Residual DiseasePhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Minimal Residual Disease

#DrugCompanyPhaseTrials

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

1 2

Beyfortus

BeiGene

Phase 2

1 3

Elunate

Takeda

Phase 2

1 4

Besponsa

WWyeth-Lederle Vaccines

Phase 2

1 5

DaraVRD/DaraVCD

UUniversity of Alabama at Birmingham

Phase 2

1 6

Toripalimab (JS001 ) Lenvatinib

SShanghai Junshi Bioscience Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Minimal Residual Disease

NCT04991103

Clinical

Trials by Indication[1]

Minimal Residual Disease1 trial

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT04991103·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DaraVRD/DaraVCD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DaraVRD/DaraVCD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DaraVRD/DaraVCD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Alabama at Birmingham

DaraVRD/DaraVCD

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Minimal Residual Disease1 trial

References

Drug Info

Quick Facts

Related News